Can we predict antibody responses in SARS-CoV-2? A cohort analysis

Article activity feed

1. 

   ScreenIT

   Mar 24, 2021

   SciScore for 10.1101/2021.03.15.21253267: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: All procedures were performed in accordance with the ethical standards of the institutional research committee of Heidelberg University (study approval number S686/2018). Consent: Written informed consent was obtained from each participant.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   At 20 hours post-infection, cells were fixed with 5% formaldehyde and immune-stained using a primary mouse antiserum binding to double-stranded RNA, a viral replication intermediate (J2 mouse antibody; Scicons, Szirák, …

   SciScore for 10.1101/2021.03.15.21253267: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IRB: All procedures were performed in accordance with the ethical standards of the institutional research committee of Heidelberg University (study approval number S686/2018). Consent: Written informed consent was obtained from each participant.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   At 20 hours post-infection, cells were fixed with 5% formaldehyde and immune-stained using a primary mouse antiserum binding to double-stranded RNA, a viral replication intermediate (J2 mouse antibody; Scicons, Szirák, Hungary) and a secondary anti-mouse horseradish peroxidase-coupled antibody (Merck, Darmstadt, Germany).	anti-mouse horseradish peroxidase-coupled antibody ( Merck , Darmstadt , Germany) . suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Neutralization assay: VeroE6 cells were seeded into 96-well plates one day before the assay.	VeroE6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   Software and Algorithms
   Sentences	Resources
   LightMix (TIB Molbiol, Berlin, Germany) for viral RNA using reverse-transcriptase polymerase chain reaction (RT-PCR) designed to detect RdRP and N genes specific for SARS-CoV-2 and the E gene for all of Sarbecovirus including SARS-CoV-2.	SARS-CoV-2 suggested: (Active Motif Cat# 91351, RRID:AB_2847848)
   1 (StataCorp LLC.	StataCorp suggested: (Stata, RRID:SCR_012763)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   This study has several limitations. The criteria for plasma donation restricted participation to healthy people under 60 years of age. Further, the survey responses showed that most participants had relatively mild COVID-19 disease, although asymptomatic participants were underrepresented and very few were hospitalized. These factors indicate that the results may not be generalizable to populations who are older than 60, have severe disease, have comorbidities, or to asymptomatic patients. Most participants only had one serum sample collected, so there is limited data on the change in antibody titers over time. The variability in the nAb response would require evaluation of larger numbers of convalescent patients in order to yield a better understanding of predictive factors. This study also has several strengths. We present the IgG response in over 200 participants and nAbs in 145 participants. We also collected follow-up data for those participants who had a strong IgG and nAbs response at baseline. The information on illness severity and PCR results from both diagnosis and convalescent time-points provided a fuller clinical picture.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
2. 

   Version published to 10.1101/2021.03.15.21253267 on medRxiv

   Mar 17, 2021